Overview
The fund is passively managed and is distinguished by broad diversification, low tracking errors, and low-cost management. The investment objective is to replicate the reference index as closely as possible and to minimize performance deviations from the benchmark. The MSCI Europe (NR) Index captures large and mid cap representation across 15 Developed Markets (DM) countries in Europe.
The investment objective is to replicate the reference index as closely as possible and to minimize performance deviations from the benchmark.
The MSCI Europe (NR) Index captures large and mid cap representation across 15 Developed Markets (DM) countries in Europe.
The fund may enter into securities lending.
Benefits
Provides access to the performance of the index with a single transaction.
Optimised risk/return profile thanks to a broad diversification across a range of sectors.
The fund offers a high degree of transparency and cost efficiency.
UCITS compliant fund.
Risks
Features
| Product category |
UBS Equity Funds UBS Index Funds Equities |
| Product domicile |
Luxembourg
|
| Portfolio management |
UBS SA国际传谋 Switzerland AG, Zurich
|
| Fund management |
UBS SA国际传谋 (Europe) S.A., Luxembourg
|
| Custodian bank |
State Street Bank International GmbH, Luxembourg Branch
|
| Representative for products established under foreign law |
UBS AG, Stockholm
|
| Day of inception |
January 7, 2019
|
| Currency of account |
EUR
|
| Close of financial year |
December 31
|
| SFDR Classification |
Art.6
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
0.11% p.a.
|
| Total expense ratio (TER) |
0.16% p.a.
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI Europe (NR) in EUR
|
| ISIN |
LU1871077761
|
| Bloomberg Ticker |
CSEQEFB LX
|
| Reuters Id |
43375944X.CHE
|
Performance and Prices
Percentage growth
as of April 23, 2026| EUR(%) | |
| YTD | |
| 1M | |
| 3M | |
| 6M | |
| 1Y | 21.87 |
| 2Y | |
| 3Y | 41.75 |
| 5Y | 62.20 |
| ø p.a.5Y | 10.16 |
Current data
| Net asset value | 23.04.2026 | EUR 216.21 |
| High - last 12 months | 27.02.2026 | EUR 221.59 |
| Low - last 12 months | 25.04.2025 | EUR 178.91 |
| Assets of the unit class in mn | 23.04.2026 | EUR 0.30 |
| Total product assets in mn | 23.04.2026 | EUR 186.98 |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 31.03.2026 | 10.60% | 12.32% |
| Sharpe Ratio | 31.03.2026 | 0.64 | 0.62 |
| Risk Free Rate | 31.03.2026 | 2.75% | 1.89% |
Structures
By the 10 largest positions (in %, as of March 31, 2026)
|
|
|
| ASML Holding NV | 3.82 |
| AstraZeneca PLC | 2.28 |
| Novartis AG | 2.18 |
| HSBC Holdings PLC | 2.11 |
| Roche Holding Ag | 2.09 |
| Shell PLC | 2.06 |
| Nestle SA | 1.92 |
| TotalEnergies SE | 1.41 |
| Siemens AG | 1.37 |
| SAP SE | 1.35 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
||
| Prospectus |
|
||
| Key Information Document |
|
|
|
| Past performance |
|
|
|
| Previous performance scenario |
|
|
|
| Statutes / Management regulations |
|
|
Document type
|
Document Language
|
| Annual report |
|
| Semi-annual report |
|